<DOC>
	<DOCNO>NCT01341405</DOCNO>
	<brief_summary>This double-blind , randomize , multicenter , phase 2b , noninferiority comparison two active dose level CG100649 vs. standard anti-arthritic dose celecoxib ( Celebrex ) .</brief_summary>
	<brief_title>Study CG100649 Versus Celecoxib Osteoarthritis Patients</brief_title>
	<detailed_description>This double-blind , randomize , multicenter , noninferiority , phase 2 study . Subjects discontinue current medication ( NSAID COX-2 inhibitor ) 5-14 day prior randomization . Paracetamol ( acetaminophen ; â‰¤2 gm/day ) may use breakthrough pain . Other NSAIDs , COX-2 inhibitor , opioids , corticosteroid may use time study . Only subject recording average WOMAC pain score 4 8 0-10 numerical rating scale washout period meeting inclusion criterion randomize study . Male female adult , age 20 older , history osteoarthritis ( OA ) knee hip diagnose radiograph obtain within past 20 year pain least 3 month OA participate study . OA must confirm radiograph diagnose accord American College Rheumatology ( ACR ) guideline . Subjects must qualify ACR global functional status I , II , III ( exclude IV ) Kellgren-Lawrence grade 1 , 2 3 ( exclude grade 4 ) . Subjects meet screen criterion randomize receive 28 day dose active dose CG100649 comparator ( celecoxib ) . Antiarthritic efficacy evaluate change Western Ontario McMaster Universities ( WOMAC ) OA index complete Day 1 ( Baseline ) Days 14 , 28 42 . The WOMAC pain subscale evaluate screening Days 1 , 7 , 14 , 21 , 28 , 35 42 . All dos administer orally daily morning . There 3 plan treatment arm ( 2 active compound + one comparator ( celecoxib ) group ) n=44 per treatment arm . Total number subject 132 . Treatment A : CG100649 : 2 mg/day ( Days 1-28 ) ; Treatment B : CG100649 : 4 mg/day ( Days 1-28 ) ; Treatment C : celecoxib : 200 mg/day ( Days 1-28 ) ; Active comparator medication identical appearance .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Males female , age 20 year old , able willing provide write informed consent participate study 2 . Confirmed osteoarthritis ( OA ) knee hip radiograph obtain within past 20 year diagnose accord American College Rheumatology ( ACR ) guideline . 3 . Subject must pain least 3 month duration osteoarthritis ( OA ) 4 . Normal blood pressure ( BP ) [ systolic BP 90140 mmHg , diastolic BP 5090 mmHg ] heart rate ( HR ) [ rest 4590 beat per minute ( bpm ) ] 5 . Subjects hypertension stably take ACE inhibitor , angiotensin II receptor ( type AT1 ) antagonist , betablocker and/or diuretic least 3 month time screen order keep normal blood pressure . Subjects change stop hypertension drug study . 6 . Clinical Chemistry must within 2x normal limit 7 . Urinalysis must within normal range . 8 . Prior randomization Day 1 , mean WOMAC pain score index joint must 4 8 010 numerical rating scale . 9 . Subjects sexual partner must agree use double barrier contraception study period 3 month afterwards provide proof surgical sterility postmenopause 1 year . 10 . Subject must able read understand follow study instruction . 1 . Use analgesic except study medication paracetamol ( acetaminophen ) time study ; 2 . Use corticosteroid intraarticular viscosupplementation within 3 month screen ; 3 . Use antidepressant anticonvulsant within 2 month screen ; 4 . Cognitive psychiatric disorder , daytime use medication ( alcohol , benzodiazepine , barbiturate , muscle relaxant ) could diminish compliance study procedure ; 5 . Use anticoagulant ( aspirin , warfarin , heparin ) within 2 week screen ; 6 . Use medication affect pain perception ( e.g . tranquilizer , hypnotic ) ; 7 . Hypersensitivity nonsteroidal antiinflammatory drug ( NSAIDs ) , cyclooxygenase ( COX ) 2 inhibitor , carbonic anhydrase inhibitor ; 8 . Use oriental medicine ( herbal medicine ) glucosamine within 14 day dose administration 9 . History drug alcohol abuse within one year prior screening ; 10 . Known allergy hypersensitivity sulfa drug ; 11 . History congestive heart failure , ischemic heart disease , peripheral arterial disease , cerebrovascular disease subject one diseases ; 12 . Use chemotherapy agent history cancer , nonmetastatic skin cancer completely excise , within five ( 5 ) year prior screen visit ; 13 . Subjects gout , pseudogout , inflammatory arthritis , Paget 's disease , chronic pain syndrome , fibromyalgia , another major joint disease ; 14 . Subjects require knee hip arthroplasty within 2 month screen anticipate need surgical procedure index joint study ; 15 . Subjects surgery affect joint within 6 month screen subject prosthesis index joint ; 16 . History seizure disorder ; 17 . Subjects serious psychosocial comorbidities ; 18 . Subjects gastrointestinal , renal , hepatic , coagulant disorder within 6 month screen ; 19 . Esophageal duodenal ulcer within 6 month screen ; 20 . History nasal polyp , bronchospasm , urticaria ; 21 . Pregnant breastfeeding ; 22 . Subject genetic problem galactose intolerance , Lapp lactose deficiency glucosegalactose malabsorption ( celecoxib contains lactose )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>